Financings in Brief: Target Therapeutics
This article was originally published in The Gray Sheet
Executive Summary
Target Therapeutics: Interventional neuroradiology products firm's board approves a two-for-one split of its common stock, the company announces Nov. 9. The split will be enacted through a stock dividend payment scheduled to be distributed Dec. 18 to all shareholders of record as of Nov. 27...